Comments
Natco Pharma Ltd has been awarded a favourable judgment in the US Court of Appeals for the Federal Circuit ruling on patent-related to Teva’s Copaxone (treat multiple sclerosis).
The court of appeals had reversed a district court’s finding related to Copaxone patent.
“This would essentially mean that Natco could launch the generic version Copaxone through its marketing partner Mylan Inc during May 2014 subject to FDA approval,’’ the company said in a release on Saturday.
The product is estimated to have clocked revenues of $3.45 billion during 2012.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.